Staff profile: Dr Maree Faux

Staff profile: Dr Maree Faux

Illuminate newsletter index page, June 2019
June 2019

Dr Maree Faux
Dr Maree Faux's research is informing new treatments for colon 
cancer.

Dr Maree Faux
Senior Postdoctoral Fellow

Describe your job: I work on colon cancer biology. I’m studying colon stem cells in specialised 3D cultures to understand how the normal colon functions, the key communication networks and what goes wrong when cancer occurs. We are using this knowledge to develop new ways to treat colon cancer.

Why do you enjoy what you do? I love the challenges of discovery and finding new ways to solve problems; I love working out the way molecules interact, and the communication networks molecules use to tell the cells what to do.

What is your favourite thing about the Institute’s culture? The Institute brings together an amazing collection of people with diverse backgrounds and ideas, and provides an environment that supports and encourages collaboration across all aspects of science.

What is one thing people would be surprised to know about you? In my early postdoc years, I was an avid rock climber, which showed me a completely different perspective on problem solving and gave me the opportunity to discover some beautiful rock places that are only accessible if you climb.

What advice would you give to a younger version of yourself? Don’t give up and remember to laugh.

Which movie star would play you in a movie adaptation of your life (and why)? My friends and family say I laugh really easily, so maybe Tamsin Greig - plus she has short hair.

What has been your professional highlight so far? Meeting and working with incredibly inspiring and talented people.

Super Content: 
Animation still image

This two-part animation from WEHI.TV explains the type of programmed cell death called apoptosis, and how the anti-cancer drug venetoclax works by forcing susceptible cells into this process.

Dr Tracy Putoczki working in the lab

A signalling molecule called interleukin-11 is a potential new target for anti-cancer therapies